I had talked about the Chinese vaccine maker Sinovac (NYSE:SVA) before in positive terms but warned that they were already at peak production and therefore had very little upside.
Well…Sinovac solved that problem by creating a joint venture with an under-utilized Chinese pharmaceutical company to goose their production. Sinovac provides expertise plus cash and the partner, Dalian Jin Gang Group, provides 100,000 square feet of manufacturing capacity.
This is a pretty big deal for Sinovac. I’m going to take a much harder look at SVA now.
More on this topic
(What's this?)
Andy Xie on China’s Empty Apartments
(naked capitalism, 8/4/10)
Sinuvac (SVA) Reports Swine Flu Success
(Contrarian Profits, 8/18/09)
Top H1N1 Drug Companies Performance: Effective Marketing
(Shocked Investor, 11/9/09)
First Gains on Swine Flu Vaccine Stocks
(Contrarian Profits, 8/26/09)
{ 1 trackback }
{ 0 comments… add one now }